Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

438 Views

I4. New vaccines

Poster Session: New Vaccines

(P-601) Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-like Particle Protein Subunit Combination Vaccine in 60–85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

MD

Matthew Davis, M.D.

Medical Director
Rochester Clinical Research
Rochester, New York, United States
CS

Craig Shapiro, DO FAOCO

Cenexel Clinical Research
Salt Lake City, Utah, United States
MA

Mark D. Adams, MD

Investigator
AMR
Lexington, Kentucky, United States
MC

Max Ciarlet, PhD

Icosavax, AstraZeneca
Seattle, Washington, United States
EA

Elizabeth M Adams, MD

Icosavax, AstraZeneca
Seattle, Washington, United States
NH

Nicholas Hourguettes, BA

Icosavax, Inc
Seattle, Washington, United States
JW

Judy Wen, BA Econ

Icosavax, AstraZeneca
Seattle, Washington, United States
WR

Wasima Rida, PhD

Icosavax, AstraZeneca
Seattle, Washington, United States
JP

Jennifer Price, BS

Icosavax, AstraZeneca
Seattle, Washington, United States

Presenting Author(s)

Lee-Jah Chang, MD (he/him/his)

Vice President, Clinical Development, Vaccines and Immune Therapies
AstraZeneca
Gaithersburg, Maryland, United States

Co-Author(s)

NK

Niranjan Kanesa-Thasan, MD

Icosavax, AstraZeneca
Seattle, Washington, United States